TD Cowen raised its price target for Regeneron Pharmaceuticals to $980, up from $960.

Oct 21, 2026, 7:05 AM ETOpinionRead the original at marketscreener.com

Good for REGN

Regeneron received a higher stock target from TD Cowen. That is a favorable analyst signal, but the report gives no new company results or plans.

REGN · Regeneron Pharmaceuticals, Inc.

AI read · Good for REGN

The AI's read

The change points to a more favorable view of Regeneron shares at TD Cowen. It is one firm's opinion, and the report gives no new company results or plans, so the support is limited.

Get alerts for REGN

Follow Regeneron Pharmaceuticals, Inc. (REGN) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for REGN

Free on the App Store and Google Play, or on the web.